Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 13/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 9/20 | 1.00 |
| ▸ | PRSS2 | P07478 | 9/20 | 1.00 |
| ▸ | PRSS3 | P35030 | 9/20 | 1.00 |
| ▸ | F2 | P00734 | 9/20 | 1.00 |
| ▸ | F9 | P00740 | 2/20 | 1.00 |
| ▸ | PROC | P04070 | 2/20 | 1.00 |
| ▸ | KLK1 | P06870 | 1/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.98 |
| ▸ | CFH | P08603 | 1/20 | 0.98 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31067656 | 1.00 | F10 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL29825652 | 1.00 | F10 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| Hydrochloric Acid SCHEMBL29377504 | 0.99 | F10 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL7742478 | 0.94 | F10 (0.89) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL13550922 | 0.93 | F10 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL7749603 | 0.92 | PRSS1 (0.88) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL19706432 | 0.91 | F10 (0.83) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL14565397 | 0.89 | CARM1 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL14565395 | 0.89 | CARM1 (1.00) | F10PRSS1PRSS2PRSS3F2 | |
| SCHEMBL3833378 | 0.86 | F10 (0.80) | F10PRSS1PRSS2PRSS3F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4180424-B1 | SUBSTITUTED PYRAZOLES AS HUMAN PLASMA KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2025-06-25 | — | — | EP | disclosed |
| US-12162838-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12116346-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| CN-113307772-B | Human plasma kallikrein inhibitors | 拜奥克里斯特制药公司 | 2024-06-28 | — | — | CN | disclosed |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2024-05-09 | — | — | US | disclosed |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | EPIGEN BIOSCIENCES, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11708332-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708333-B2 | Human plasma kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230094305-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-03-30 | — | — | US | disclosed |
| US-20090285887-A1 | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor | GLAXO GROUP LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20080026474-A1 | ASSAY FOR DIFFERENTIATING COMPOUNDS THAT MODULATE THE EXTRINSIC AND/OR INTRINSIC COAGULATION PATHWAYS | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026447-A1 | Assay for determining factor viia inhibitor concentration in plasma samples | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20080026447-A1 | Assay for determining factor viia inhibitor concentration in plasma samples | BRISTOL-MYERS SQUIBB COMPANY | 2008-01-31 | — | — | US | disclosed |
| US-20070105825-A1 | Concurrent drugs | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| WO-2007047608-A2 | FIBRIN TARGETED THERAPEUTICS | EPIX PHARMACEUTICALS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070082840-A1 | Combination therapy for inhibition of platelet aggregation | VDDI PHARMACEUTICALS | 2007-04-12 | — | — | US | disclosed |
| WO-2005087266-A1 | COMBINATION THERAPY FOR INHIBITION OF PLATELET AGGREGATION | VDDI PHARMACEUTICALS (US) | 2005-09-22 | — | — | WO | disclosed |
| US-6794412-B1 | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
| US-6794412-B1 | Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090285887-A1 | Pharmaceutical Composition Comprising A Plurality of Mini-Tablets Comprising A Factor XA Inhibitor | F12, TFPI, PLAT | F10 11/4885PRSS1 79/4885PRSS2 106/4885 |
| US-12116346-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F10 112/4885PRSS1 43/4885PRSS2 103/4885 |
| US-20240150296-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F10 112/4885PRSS1 43/4885PRSS2 103/4885 |
| US-11708332-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F10 115/4885PRSS1 40/4885PRSS2 94/4885 |
| US-20230094305-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK1, KLK5 | F10 118/4885PRSS1 29/4885PRSS2 65/4885 |
| US-20240150295-A1 | HUMAN PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | F10 112/4885PRSS1 43/4885PRSS2 103/4885 |
| US-20070105825-A1 | Concurrent drugs | CYP3A5, HPSE, SLC9A5 | F10 64/4885PRSS1 347/4885PRSS2 438/4885 |
| US-11708333-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK1, KLK5 | F10 118/4885PRSS1 29/4885PRSS2 65/4885 |
| US-20230286928-A1 | HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF DISEASE | LPAR1, LPAR2, LPAR4 | F10 2810/4885PRSS1 1903/4885PRSS2 2615/4885 |
| US-12162838-B2 | Human plasma kallikrein inhibitors | KLKB1, KLK5, KLK1 | F10 112/4885PRSS1 43/4885PRSS2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.